Резюме: Гречихина Мария Владимировна

Адрес

Федеральное государственное бюджетное учреждение науки Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук, Москва, Россия

Контакты

https://www.ibch.ru/users/392

Работа в ИБХ

2005–наст.вр.	Младший научный сотрудник	

Навыки

Работаю с культурами клеток с 2003 года, с большим количеством разных клеточных линий одновременно - с 2014 года. Составляю коллекцию клеточных линий, клетки для которой выращиваются по правилам клеточного банка, т е без антибиотиков и при максимально возможном исключении взаимной контаминации линий.

Также владею методами: проточная цитометрия, МТТ-тест, ИФА, измерение уровня АТФ при помощи хемилюминесценции.

Владение языками

русский, английский

Научные интересы

Иммунология, клеточные линии, банк клеток

Публикации

1. Shagdarova BT, Okara PS, Efremov MA, Lunkov AP, Vasilyeva NI, **Grechikhina MV**, Akopov SB, Svirshchevskaya EV (2026). Stimulating Effect of W. somnifera Extracts Encapsulated into Chitosan Nanoparticles. *Russ. J. Bioorganic Chem.* 52 (5), 106, 10.1134/S1068162026601394
2. Palamarchuk AI, Ustiuzhanina MO, Velichinskii RA, Vavilova JD, **Grechikhina MV**, Kovalenko EI, Streltsova MA (2026). Interplay of telomerase non-canonical functions in NK cell resistance to iCasp9-mediated apoptosis. *Cell Death Discov* 12 (1), , 10.1038/s41420-026-03183-y
3. Velichinskii RA, Streltsova MA, Vavilova JD, Boyko AA, Belovezhets TN, **Grechikhina MV**, Kovalenko EI (2025). PSCA-CAR-NK cells exert cytotoxic activity against PSCA-expressing tumor cells and are characterized by a specific chemokine profile. *Cytotherapy* 27 (12), 1384–1395, 10.1016/j.jcyt.2025.08.001
4. Shevchenko MA, Ovsyanikova OV, **Grechikhina MV**, Garbuz DG, Boyko AA, Evgenev MB, Zatsepina OG, Kovalenko EI, Sapozhnikov AM (2025). HSP70-NK and Target Cell Interactions: Implication to the Anticancer Effects. *Biochem (Mosc) Suppl Ser A Membr Cell Biol* 19 (1), 79–83, 10.1134/S1990747824700491
5. Streltsova MA, Boyko AA, Alekseeva NA, Proshkina GM, Shramova EI, **Grechikhina MV**, Shevchenko MA, Shustova OA, Popodko AI, Konovalova EV, Schulga AA, Sapozhnikov AM, Deyev SM, Kovalenko EI (2025). Genetically modified NK cells equipped with a switchable CAR for the treatment of HER2-positive cancers. *Biochimie* 238 (Pt B), 30–42, 10.1016/j.biochi.2025.07.021
6. Svirshchevskaya EV, Kostenko VV, Boyko AA, Shevtsov Ь, Kholodenko RV, **Grechikhina MV**, Gracheva

IA, Fedorov AY, Sapozhnikov AM (2024). Core–Shell Chitosan Particles Targeting Membrane-Bound Heat Shock Protein 70 for Cancer Therapy. *Nanomaterials (Basel)* 14 (23), 1873, 10.3390/nano14231873

7. Alekseeva NA, Boyko AA, Shevchenko MA, **Grechikhina MV**, Streltsova MA, Alekseeva LG, Sapozhnikov AM, Deyev SM, Kovalenko EI (2024). Three-Dimensional Model Analysis Revealed Differential Cytotoxic Effects of the NK-92 Cell Line and Primary NK Cells on Breast and Ovarian Carcinoma Cell Lines Mediated by Variations in Receptor–Ligand Interactions and Soluble Factor Profiles. *Biomedicines* 12 (10), 2398, 10.3390/biomedicines12102398
8. Streltsova MA, Palamarchuk AI, Vavilova JD, Ustiuzhanina MO, Boyko AA, Velichinskii RA, Alekseeva NA, **Grechikhina MV**, Shustova OA, Sapozhnikov AM, Kovalenko EI (2024). Methodological Approaches for Increasing the Retroviral Transduction Efficiency of Primary NK Cells. *Curr Pharm Des* 30 (37), 2947–2958, 10.2174/0113816128314633240724060916
9. Alekseeva LG, Ovsyanikova OV, Schulga AA, **Grechikhina MV**, Shustova OA, Kovalenko EI, Svirshchevskaya EV, Deyev SM, Sapozhnikov AM (2024). Targeted Delivery of HSP70 to Tumor Cells via Supramolecular Complex Based on HER2-Specific DARPin9_29 and the Barnase:Barstar Pair. *Cells* 13 (4), , 10.3390/cells13040317
10. Kostenko VV, Boyko AA, **Grechikhina MV**, Ovsyanikova OV, Sapozhnikov AM (2024). Expression of membrane HSP70 on tumor cells during cultivation in 3D cultures. *Medical Immunology (Russia)* 26 (4), 657–662, 10.15789/1563-0625-EOM-16750
11. Ovsyanikova OV, Shustova OA, **Grechikhina MV**, Sapozhnikov AM (2024). Flow cytometric analysis of the interaction of monoclonal antibodies to various epitopes of the HSP70 molecule with intracellular and membrane-associated forms of this protein. *Medical Immunology (Russia)* 26 (5), 905–912, 10.15789/1563-0625-FCA-16716
12. Alekseeva NA, Ustyuzhanina MO, Streltsova MA, **Grechikhina MV**, Lutsenko GV, Kovalenko EI (2023). NK CELL EXPANSION IN VITRO IS FOLLOWED BY LOSS OF INHIBITORY KIR EXPRESSION. *Medical Immunology (Russia)* 25 (3), 441–446, 10.15789/1563-0625-NCE-2845
13. Streltsova MA, Boyko AA, Ustiuzhanina MO, Palamarchuk AI, Alekseeva NA, Velichinskii RA, Vavilova JD, **Grechikhina MV**, Sapozhnikov AM, Deev SM, Kovalenko EI (2022). Subpopulation Heterogeneity of NK Cells during the Genetic Modification for Subsequent Use in Targeted Therapy. *Dokl Biochem Biophys* 507 (1), 380–382, 10.1134/S1607672922340142
14. Kalinovsky DV, Kibardin AV, Kholodenko IV, Svirshchevskaya EV, Doronin II, Konovalova MV, **Grechikhina MV**, Rozov FN, Larin SS, Deyev SM, Kholodenko RV (2022). Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors. *J Immunother Cancer* 10 (6), , 10.1136/jitc-2022-004646
15. Vavilova JD, Boyko AA, Troyanova NI, Ponomareva NV, Fokin VF, Fedotova EY, Streltsova MA, Kust SA, **Grechikhina MV**, Shustova OA, Azhikina TL, Kovalenko EI, Sapozhnikov AM (2022). Alterations in Proteostasis System Components in Peripheral Blood Mononuclear Cells in Parkinson Disease: Focusing on the HSP70 and p62 Levels. *Biomolecules* 12 (4), , 10.3390/biom12040493
16. Palamarchuk AI, Alekseeva NA, Streltsova MA, Ustiuzhanina MO, Kobyzeva PA, Kust SA, **Grechikhina MV**, Boyko AA, Shustova OA, Sapozhnikov AM, Kovalenko EI (2021). Increased susceptibility of the CD57− NK cells expressing KIR2DL2/3 and NKG2C to iCasp9 gene retroviral transduction and the relationships with proliferative potential, activation degree, and death induction response. *Int J Mol Sci* 22 (24), , 10.3390/ijms222413326
17. Vavilova JD, Boyko AA, Ponomareva NV, Fokin VF, Fedotova EY, Streltsova MA, Kust SA, **Grechikhina MV**, Bril EV, Zimnyakova OS, Kovalenko EI, Sapozhnikov AM (2021). Reduced Immunosenescence of Peripheral Blood T Cells in Parkinson's Disease with CMV Infection Background. *Int J Mol Sci* 22 (23), , 10.3390/ijms222313119
18. **(конференция)** Вавилова ЮД, Бойко АА, **Гречихина МВ**, Коваленко ЕИ, Сапожников АМ (2021). Phenotypic changes in peripheral blood Tlymphocytes in patients with Parkinson's disease. *FEBS Open Bio* , 463, 10.1002/2211-5463.13205

19. Erokhina SA, Streltsova MA, Kanevskiy LM, **Grechihina MV**, Sapozhnikov AM, Kovalenko EI (2020). HLA-DR-expressing NK cells: Effective killers suspected for antigen presentation. *J Leukoc Biol* 109 (2), 327–337, 10.1002/JLB.3RU0420-668RR
20. Vavilova YD, Boyko AA, Kovalenko EI, **Grechikhina MV**, Shustova OA, Azhikina TL, Sapozhnikov AM (2020). Analysis of the association of the polymorphism of the CLIC1, MSH5, C6orf26, C6orf25 genes with the expression level of the HSPA1B gene. *Medical Immunology (Russia)* 22 (4), 779–784, 10.15789/1563-0625-AOT-1629
21. Malinovskaya YA, Kovalenko EI, Kovshova TS, Osipova NS, Maksimenko OO, Balabanyan VY, Razzhivina VA, **Grechikhina MV**, Boiko AA, Gelperina SE (2020). CYTOTOXICITY AND HEMOCOMPATIBILITY OF DOXORUBICIN-LOADED PLGA NANOPARTICLES. *РБЖ* 19 (1), 71–80, 10.17650/1726-9784-2019-19-1-71-80
22. Svirshchevskaya E, Doronina E, **Grechikhina M**, Matushevskaya E, Kotsareva O, Fattakhova G, Sapozhnikov A, Felix K (2019). Characteristics of multicellular tumor spheroids formed by pancreatic cells expressing different adhesion molecules. *Life Sci II* S0024 (19), 30048–7, 10.1016/j.lfs.2019.01.034
23. Streltsova MA, Erokhina SA, Kanevskiy LM, **Grechikhina MV**, Kobyzeva PA, Lee DA, Telford WG, Sapozhnikov AM, Kovalenko EI (2019). Recurrent Stimulation of Natural Killer Cell Clones with K562 Expressing Membrane-Bound Interleukin-21 Affects Their Phenotype, Interferon-γ Production, and Lifespan. *Int J Mol Sci* 20 (2), , 10.3390/ijms20020443
24. Kanevskiy LM, **Grechikhina MV**, Kuzmina EG, Mushkarina TY, Spelkov AA, Streltsova MA, Kovalenko EI (2019). Distribution of mica alleles in the Russian population.*Medical Immunology (Russia)* 21 (5), 959–964, 10.15789/1563-0625-2019-5-959-964
25. **(конференция)** Вавилова ЮД, Бойко АА, Шустова ОА, **Гречихина МВ**, Доронина ЕВ, Троянова НИ, Коваленко ЕИ, Сапожников АМ (2019). A comparative study of apoptosis in peripheral blood leukocytes in patients with Parkinson's disease and healthy donors. *Cell Death Discov* , , https://doi.org/10.1038/s41420-018-0128-4
26. Sapozhnikov AM, Klinkova AV, Shustova OA, **Grechikhina MV**, Kilyachus MS, Stremovskiy OA, Kovalenko EI, Deyev SM (2018). A Novel Approach to Anticancer Therapy: Molecular Modules Based on the Barnase:Barstar Pair for Targeted Delivery of HSP70 to Tumor Cells. *Acta Naturae* 10 (3), 85–91, 10.32607/20758251-2018-10-3-85-91
27. Lutsenko GV, **Grechikhina MV**, Efremov MA (2018). Autocrine Survival Factors of a Cytotoxic CTLL-2 Cell Line. *Biochem (Mosc) Suppl Ser A Membr Cell Biol* 12 (3), 239–246, 10.1134/S1990747818030066
28. Lutsenko GV, **Grechikhina MV**, Efremov MA (2018). Survival autocrine factors of cytotoxic cell line CTLL-2. *BIOL MEMBRANY* 35 (4), 271–279, 10.1134/S0233475518040096
29. Koloskova OO, Gileva AM, Drozdova MG, **Grechihina MV**, Suzina NE, Budanova UA, Sebyakin YL, Kudlay DA, Shilovskiy IP, Sapozhnikov AM, Kovalenko EI, Markvicheva EA, Khaitov MR (2018). Effect of lipopeptide structure on gene delivery system properties: Evaluation in 2D and 3D in vitro models. *Colloids Surf B Biointerfaces* 167, 328–336, 10.1016/j.colsurfb.2018.04.003
30. Konovalova M, Shagdarova B, Zubareva A, Generalov A, **Grechikhina M**, Svirshchevskaya E (2018). Development of mucoadhesive Chitosan-based drug delivery system. *Prog Chem Appl Chitin Deriv* 23, 103–113, 10.15259/PCACD.23.10
31. Svirshchevskaya EV, Zubareva AA, Boyko AA, Shustova OA, **Grechikhina MV**, Shagdarova BT, Varlamov VP (2016). Analysis of toxicity and biocompatibility of chitosan derivatives with different physico-chemical properties. *APPL BIOCHEM MICRO+* 52 (5), 483–490, 10.1134/S000368381605015X
32. Belova OV, Sergienko VI, Arion VY, Lukanidina TA, Moskvina SN, Zimina IV, Borisenko GG, Lutsenko GV, **Grechikhina MV**, Kovaleva EV, Klyuchnikova ZI (2014). Purification of high-molecular-weight subfraction from porcine skin inhibiting proliferation of A431 human carcinoma epidermoid cells. *Bull Exp Biol Med* 157 (3), 371–374, 10.1007/s10517-014-2569-y
33. Kovalenko EI, Boyko AA, Semenkov VF, Lutsenko GV, **Grechikhina MV**, Kanevskiy LM, Azhikina TL, Telford WG, Sapozhnikov AM (2014). ROS production, intracellular HSP70 levels and their relationship in human neutrophils: Effects of age. *Oncotarget* 5 (23), 11800–11812, 10.18632/oncotarget.2856

34. Луценко ГВ, **Гречихина МВ**, Дьячкова ЛГ, Сапожников АМ (2013). Протективное действие аутокринных факторов цитотоксических Т-лимфоцитов в условиях химической гипоксии. 34 (5), 251–254.
35. Lutsenko GV, **Grechikhina MV**, Diachkova LG, Sapozhnikov AM (2013). Protective action of autocrine factors of cytotoxic T lymphocytes under chemical hypoxia conditions. *Immunologiya* 34 (5), 251–254.
36. Луценко ГВ, **Гречихина МВ**, Дьячкова ЛГ (2009). О влиянии дефицита аутокринных факторов в культуре на протекание апоптоза в цитотоксических Т-клетках. 30 (1), 4–7.
37. Lutsenko GV, **Grechikhina MV**, Diachkova LG, Lutsan NI (2008). Survival of T-lymphocytes under alkalosis and autocrine factor deficiency. *Biochem (Mosc) Suppl Ser A Membr Cell Biol* 2 (4), 318–325, 10.1134/S1990747808040041
38. Lutsenko GV, **Grechikhina MV**, Diachkova LG, Lutsan NI (2008). T-lymphocyte survival under conditions of alkalosis and autocrine factor deficiency. *BIOL MEMBRANY* 25 (6), 463–471.
39. Lutsenko GV, **Grechikhina MV**, Diachkova LG (2008). Autocrine factor participation in defence of cytotoxic CTLL-2 cells from oxidative stress. *Tsitologiia* 50 (6), 492–499.
40. Lutsenko GV, **Grechikhina MV**, Diachkova LG (2008). Autocrine factors in defense of cytotoxic CTLL-2 cells from oxidative stress. *Cell tissue biol* 2 (3), 239–245, 10.1134/S1990519X08030048
41. Луценко ГВ, **Гречихина МВ**, Дьячкова ЛГ, Луцан НИ (2008). О выживании Т-лимфоцитов в условиях алкалоза и дефицита аутокринных факторов. 25 (6), 463–471.
42. Луценко ГВ, **Гречихина МВ**, Дьячкова ЛГ (2008). Участие аутокринных факторов в защите клеток цитотоксической линии CTLL-2 от окислительного стресса. 50 (6), 492–499.
43. Lutsenko GV, **Grechikhina MV**, Diachkova LG, Lutsan NI (2007). Influence of autocrine factor deficit in culture on survival and energy metabolism of CTLL-2 cells under oxidative stress. *Tsitologiia* 49 (4), 284–291.
44. Lutsenko GV, **Grechikhina M**, Dyachkova LG, Lutsan NI (2007). Effects of an autocrine factor deficit on the survival and energy metabolism of CTLL-2 cells under oxidative stress conditions in culture. *Cell tissue biol* 1 (3), 235–243, 10.1134/S1990519X07030054
45. Луценко ГВ, **Гречихина МВ**, Дьячкова ЛГ, Луцан НИ (2007). Влияние дефицита аутокринных факторов в культуре на выживание и энергетический метаболизм клеток линии CTLL-2 в условиях окислительного стресса. 49 (4), 284–291.
46. Луценко ГВ, **Гречихина МВ**, Дьячкова ЛГ (2005). Регуляция уровня АТФ в нормальных и трансформированных Т-клетках аутокринными факторами. 26, 91–95.